Search

Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy

Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve.

Jeffrey Zwicker, MD, has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and Beth Israel Deaconess Medical Center (BIDMC), where he served as Chief of Benign Hematology in the Division of Hematology since 2017. Dr. Zwicker succeeds MSK’s Interim Hematology Service Chief, Marcel van den Brink, MD, PhD.

In honor of Women's History Month, meet the scientific hero who helped raise money and awareness for AIDS research.

In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role in these successes, as they work together with the common goal of using their discoveries to create new treatments for people with cancer.

The list honors health care leaders who envision a better future for all New Yorkers.

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.